Among active 13F managers last quarter, 2 opened and 3 added, while 2 reduced; the largest holder to move was Perceptive Advisors LLC (+0.0%). No open-market insider trades in the last 180 days.
Funds lean in and no leg opposes.
22 tracked 13F filers disclose a position in ADGM as of the latest SEC 13F filings, a combined $10.7M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Perceptive Advisors LLC | 9.9M | $6.4M | ▲~0% Added · +10 sh | Q2 2026 | |
| 2 | Adage Capital Partners GP, L.L.C. | 1.3M | $1.4M | —Held | Q1 2026 | |
| 3 | ADAR1 Capital Management, LLC | 1.2M | $1.4M | ▲+4.0% Added · +46K sh | Q1 2026 | |
| 4 | Alyeska Investment Group, L.P. | 1.2M | $756K | —Held | Q2 2026 | |
| 5 | Silverarc Capital Management, LLC | 224K | $146K | ▼−11% Reduced · −28K sh | Q2 2026 | |
| 6 | Shaolin Capital Management LLC | 171K | $112K | —Held | Q2 2026 | |
| 7 | Vanguard Capital Management LLC | 109K | $71K | ▲+175% Added · +69K sh | Q2 2026 | |
| 8 | Affinity Asset Advisors, LLC | 80K | $92K | —Held | Q1 2026 | |
| 9 | Geode Capital Management, LLC | 79K | $52K | ▼−37% Reduced · −46K sh | Q2 2026 | |
| 10 | Vanguard Fiduciary Trust Co | 54K | $35K | —Held | Q2 2026 | |
| 11 | Toronto Dominion Bank | 25K | $29K | —Held | Q1 2026 | |
| 12 | XTX Topco Ltd | 23K | $27K | ▲+29% Added · +5K sh | Q1 2026 | |
| 13 | Northern Trust Corp | 22K | $25K | —Held | Q1 2026 | |
| 14 | Opaleye Management Inc. | 18K | $13K | —Held | Q2 2026 | |
| 15 | Renaissance Technologies LLC | 17K | $19K | ▲New +17K sh | Q1 2026 | |
| 16 | Citadel Advisors LLC | 16K | $11K | ▲New +16K sh | Q2 2026 | |
| 17 | Bank Of America Corp | 13K | $15K | ▲+12% Added · +1K sh | Q1 2026 | |
| 18 | Tower Research Capital LLC (TRC) | 2K | $3K | ▼−73% Reduced · −6K sh | Q1 2026 | |
| 19 | JPMorgan Chase & Co | 975 | $1K | ▲New +975 sh | Q1 2026 | |
| 20 | Crewe Advisors LLC | 500 | $326 | —Held | Q2 2026 | |
| 21 | Morgan Stanley | 137 | $158 | —Held | Q1 2026 | |
| 22 | Citigroup Inc | 1 | $1 | ▲New +1 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 2 funds opened a new position in ADGM and 3 added to an existing one, while 2 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Revolution Medicines IncRVMD | 10 funds | $909.6M |
| Unitedhealth Group IncUNH | 9 funds | $1.1B |
| Praxis Precision Medicines IPRAX | 9 funds | $1.1B |
| Intuitive Surgical IncISRG | 9 funds | $883.9M |
| Rhythm Pharmaceuticals IncRYTM | 9 funds | $585.4M |
| Insmed IncINSM | 9 funds | $534.6M |
| Danaher CorpDHR | 9 funds | $484.1M |
| Biogen IncBIIB | 9 funds | $462.7M |
| Guardant Health IncGH | 9 funds | $445.5M |
| Oruka Therapeutics IncORKA | 9 funds | $312.4M |
| Xenon Pharmaceuticals IncXENE | 9 funds | $295.5M |
| Immunovant IncIMVT | 9 funds | $171.8M |
Ranked by how many of ADGM's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in ADGM.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Dec 16, 2025 | Kaster Deborah | Chief Financial Officer | Buy (P) | 15K | $18K |
| Dec 12, 2025 | Usen Todd | Chief Executive Officer, Director | Buy (P) | 207K | $226K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 5 | 3 | – |
Insiders Form 4 open-market | 0 | 0 | $0 |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for ADGM
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ADGM/capital-change-brief"
Use Arkolith's capital_change_brief for ADGM. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for ADGM. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.